Key Takeaways
- • Aevius, a health-AI startup, has raised $22 million, according to the Wall Street Journal's reporting on the round.
- • The founding team previously built Modella AI, which drugmaker AstraZeneca acquired in January 2026.
- • Aevius aims to use AI to help healthcare providers, life sciences companies and health insurers make better use of their data.
- • The company represents a broader ambition for the team than Modella's cancer-focused biomedical work.
Summary
Modella AI was a cancer-focused biomedical startup that drugmaker AstraZeneca acquired in January. According to the WSJ, the team behind Modella is now back with a new company and a broader mandate. Aevius seeks to apply artificial intelligence to help healthcare providers, life sciences companies and health insurers better use the data they hold.
The primary source is a brief newsletter item and does not disclose the investors in the round, valuation, or detailed product plans. Readers seeking further detail on the financing terms or the company's commercial roadmap should consult the full WSJ report.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.